Soleno TherapeuticsSLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 92
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
16% more funds holding
Funds holding: 142 [Q3] → 165 (+23) [Q4]
2% less call options, than puts
Call options by funds: $120M | Put options by funds: $123M
4% less capital invested
Capital invested by funds: $2.38B [Q3] → $2.29B (-$85M) [Q4]
2.86% less ownership
Funds ownership: 121.22% [Q3] → 118.37% (-2.86%) [Q4]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Guggenheim Debjit Chattopadhyay 21% 1-year accuracy 6 / 28 met price target | 29%upside $97 | Buy Maintained | 8 May 2025 |
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 40%upside $105 | Outperform Maintained | 8 May 2025 |
Piper Sandler Yasmeen Rahimi 24% 1-year accuracy 5 / 21 met price target | 93%upside $145 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 110 / 305 met price target | 33%upside $100 | Buy Reiterated | 15 Apr 2025 |
Stifel James Condulis 67% 1-year accuracy 2 / 3 met price target | 44%upside $108 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SLNO published over the past 30 days









